🇪🇺 Vipdomet in European Union

EMA authorised Vipdomet on 18 September 2013

Marketing authorisation

EMA — authorised 18 September 2013

  • Application: EMEA/H/C/002654
  • Marketing authorisation holder: Takeda Pharma A/S
  • Local brand name: Vipdomet
  • Indication: Vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus: as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin; in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone; in combination with insulin (i.e. triple
  • Status: approved

Read official source →

Vipdomet in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is Vipdomet approved in European Union?

Yes. EMA authorised it on 18 September 2013.

Who is the marketing authorisation holder for Vipdomet in European Union?

Takeda Pharma A/S holds the EU marketing authorisation.